Galectin-3 is associated with the functional outcome and mortality in stroke patients: A systematic review and meta-analysis

Han, Xiaoling; Geng, Bingbing; Deng, Fei‐Yan; Ying, Ma; Fan, Ningning; Huang, Shaomin; Xue, Ming; Wu, Lei; Li, Bixia; Liao, Shaoqin; Ye, Qiao; Liu, Yu

doi:10.1016/j.heliyon.2023.e13279

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have revealed that galectin-3 plays an important role as a diagnostic or prognostic biomarker for neurodegenerative disorders, certain types of heart disease, viral infection, autoimmune disease, and tumors 27–29 . Additionally, LGALS3 could serve as a novel marker for the prediction of stroke clinical prognosis, positively associated with poor functional outcome and an increased risk of mortality in stroke patients 30,31 . Our data on the ROC analysis of LGALS3 (AUC=0.794) in the differentiation of the stroke with poor and good prognosis were consistent with this result.…”

Section: Discussionmentioning

confidence: 99%

An inflammation-derived and clinical-based model for ischemic stroke recovery

Luo,

Cai,

Xiao

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundNeuroinflammatory responses reflecting disease progression are believed to be closely associated with the severity of prognosis in post-stroke.PurposeThis study developed a combined predicted model of inflammation-derived biomarkers and clinical-based indicators using machine learning algorithms for differentiation of the functional outcome in patients with subacute ischemic stroke.MethodsClinical blood samples and patient data from individuals with subacute ischemic stroke were collected at admission. Based on activities of daily living assessments followed by a 3-month recovery, patients were categorized into two groups: those with little effective recovery (LE) and those with obvious effective recovery (OE). Serum samples underwent proteomic testing for initial candidates. Subsequently, multidimensional validation of candidates in models of ischemia-reperfusion at protein and mRNA levels was performed.T-test, Receiver Operating Characteristic (ROC), and LASSO analysis in an additional cohort were performed to confirm the clinical variables and candidate biomarkers in the discriminatory sensitivity and specificity between the LE and OE groups. Finally, models were developed based on candidates in the training dataset and predicted stroke recovery outcomes in another new dataset using ten standard two-categorical variable algorithms in machine learning.ResultsWe identified higher tissue inhibitor metalloproteinase-1 (TIMP1) and LGALS3 levels were positively correlated with the severity of prognosis after ischemic stroke rehabilitation. TIMP1 (AUC=0.904, 0.873) and LGALS3 (AUC=0.995, 0.794) were confirmed to address superior sensitivity and specificity in distinguishing ischemic stroke from healthy control and LE group from OE group. The TIMP1 and Lgals3 expression exhibited an evident increase in microglia following ischemia-reperfusion. In addition, inflammation-derived biomarkers (TIMP1, LGALS3) coupled with clinical-based indicators (HGB, LDL-c, UA) were built in a combined model with random forest to differentiate OE from LE in 3-month follow-up with high accuracy (AUC = 0.8).ConclusionOur findings provided evidence supporting the critical prognostic potential and risk prediction of inflammation-derived biomarkers after ischemic stroke rehabilitation in complementary to current clinical-based parameters.

show abstract

Section: Discussionmentioning

confidence: 99%

An inflammation-derived and clinical-based model for ischemic stroke recovery

Luo,

Cai,

Xiao

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…5,9,[14][15][16] The dual effects of Galectin-3 on the AIS appear to be significantly time dependent. Clinical studies have shown that Galectin-3 at baseline has potential value in the diagnosis and prediction of clinical outcomes in patients with AIS [17][18][19][20] and is expected to have therapeutic potential as a poststroke immunomodulatory molecule. 21 A study involving 3082 patients with AIS showed that high baseline Galectin-3 levels are associated with poor prognosis, poststroke death, and severe disability.…”

Section: Introductionmentioning

confidence: 99%

Dynamic Changes and Clinical Significance of Plasma Galectin-3 in Patients with Acute Ischemic Stroke Undergoing Endovascular Therapy

Yao,

Liang,

Zeng

et al. 2024

JIR

View full text Add to dashboard Cite

Purpose Galectin-3 is a key regulator of microglial proliferation and activation and may have dual and time-dependent effects on ischemic stroke. This study aimed to prospectively investigate the dynamic changes in Galectin-3 levels in patients with acute ischemic stroke receiving endovascular therapy and its clinical significance. Patients and Methods A total of 105 patients with acute ischemic stroke who underwent endovascular therapy were prospectively enrolled. Plasma Galectin-3 was quantitatively detected by an enzyme-linked immunosorbent assay before the operation and at 1 day, 3 days and 7 days after the operation. A linear mixed-effect model, Pearson correlation analysis and receiver operating characteristic (ROC) curve analysis were used to evaluate the dynamic changes in the plasma Galectin-3 concentration and its relationship with clinical outcomes. Results Increases in plasma Galectin-3 levels at 1 day and 3 days after surgery were associated with early neurological deterioration and death (both P <0.05). Increased Galectin-3 levels before surgery and at 1 day and 3 days after surgery were associated with poor prognosis ( P <0.05). Pearson correlation analysis revealed that Galectin-3 levels before surgery ( r =0.318, P =0.002), at 1 day ( r =0.318, P =0.001), 3 days ( r =0.429, P < 0.001) and 7 days after surgery ( r =0.340, P =0.001) were positively correlated with NIHSS scores. The ROC curve results showed that Galectin-3 concentration had a certain predictive value for death at 1 day (AUC=0.707, P=0.013), 3 days (AUC=0.708, P=0.016) and 7 days after the operation (AUC=0.708, P=0.016), but this predictive value was lower than that of the NIHSS score. Conclusion In acute ischemic stroke patients receiving endovascular therapy, an increase in the plasma Galectin-3 levels were associated with death, poor prognosis, and early neurological deterioration. Galectin-3 levels were significantly correlated with the NIHSS score and had a certain predictive value for death.

show abstract

Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose–response meta-analysis

Bellos,

Marinaki,

Lagiou

et al. 2024

Int Urol Nephrol

View full text Add to dashboard Cite

Background Galectin-3 has been proposed as a candidate marker for cardiovascular risk stratification, although its role in kidney failure is unclear. The aim of this systematic review was to assess the association of serum galectin-3 levels with overall survival and cardiovascular outcomes among hemodialysis patients. Methods Medline, Scopus, Web of Science and CENTRAL were systematically searched from inception till Aug 20, 2023. Observational studies evaluating the association of serum galectin-3 with mortality, cardiovascular disease and arterial stiffness in hemodialysis patients were included. The exposure–response relationship between galectin-3 and mortality was explored by dose–response meta-analysis using restricted cubic splines in a one-stage approach. Results Overall, 13 studies were included (9 cohort and 4 cross-sectional), comprising 6025 hemodialysis individuals. Increasing galectin-3 values were associated with greater all-cause mortality risk (χ2: 18.71, p-value < 0.001) and an insignificant trend toward higher cardiovascular mortality risk (χ2: 5.06, p-value: 0.079). Compared to a reference galectin-3 value of 10 ng/ml, all-cause mortality risk was significantly higher with levels of 20 ng/ml (Hazard ratio–HR: 2.62, 95% confidence intervals-CI: 1.66–4.15), 30 ng/ml (HR: 3.78, 95% CI: 2.05–6.97) and 40 ng/ml (HR: 4.01, 95% CI: 2.14–7.52). Qualitative synthesis of evidence indicated that serum galectin-3 may be linked to abdominal aortic calcification severity and progression, as well as to left ventricular systolic and diastolic dysfunction. Conclusions This study suggests that high serum galectin-3 levels are associated with greater all-cause mortality risk among patients on maintenance hemodialysis. Preliminary cross-sectional evidence indicates that serum galectin-3 may be associated with arterial stiffness and left ventricular dysfunction.

show abstract

Galectin-3 is associated with the functional outcome and mortality in stroke patients: A systematic review and meta-analysis

Cited by 4 publications

References 30 publications

An inflammation-derived and clinical-based model for ischemic stroke recovery

An inflammation-derived and clinical-based model for ischemic stroke recovery

Dynamic Changes and Clinical Significance of Plasma Galectin-3 in Patients with Acute Ischemic Stroke Undergoing Endovascular Therapy

Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose–response meta-analysis

Contact Info

Product

Resources

About